Compass Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Compass Therapeutics, Inc. | CMPX - NASDAQ |
Postponed | $0.00 | $0.00 | Postponed | 10/13/2020 |
| Citigroup, Credit Suisse, Stifel | ||||||
Co-Manager(s): Raymond James | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-10-19 Terms Added 2020-11-09 | ||||||
About Compass Therapeutics, Inc. (adapted from Compass Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CMPX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.